This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Organon & Co. Class Action Lawsuit
Business class action lawsuit

Organon & Co. Class Action Lawsuit

Analysis based on 12 articles · First reported May 29, 2025 · Last updated Jun 12, 2025

Sentiment
-50
Attention
2
Articles
12
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market is impacted by the significant decline in Organon & Co.'s stock price, which fell over 27% in a single day following the news of its dividend decrease. This event highlights potential risks for investors in Organon & Co. due to alleged misleading statements.

Pharmaceuticals
Event Summary

The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit. The lawsuit alleges that Organon & Co. made materially false and misleading statements and concealed adverse facts concerning its capital allocation and debt reduction strategy, particularly after its acquisition of Roivant Sciences. This allegedly led to a 70% decrease in the regular quarterly dividend, causing Organon & Co.'s stock price to drop dramatically by over 27% on May 1, 2025. Shareholders who purchased shares between October 31, 2024, and April 30, 2025, are encouraged to contact The Gross Law Firm, with a deadline of July 22, 2025, to seek lead plaintiff appointment.

Key Actions
95 Organon & Co. decreased dividend
Entities Involved
stock
Organon & Co.
Organon & Co. is facing a class action lawsuit for allegedly making false and misleading statements regarding its capital allocation and debt reduction strategy, which led to a significant drop in its stock price.
Importance 100.0 Sentiment -70.0
priv
Roivant Sciences
Organon & Co.'s acquisition of Roivant Sciences is cited as a factor influencing Organon & Co.'s debt reduction strategy, which allegedly led to the dividend decrease.
Importance 30.0 Sentiment 0.0
Relationships
Organon & Co. acquirer ↔ Roivant Sciences Organon & Co. acquired Roivant Sciences for $1.2 billion in October 2024, a transaction that significantly increased its
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.